What is the safety of tramadol (tramadol hydrochloride) in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Tramadol is not recommended for use in pediatric patients under 18 years old due to significant safety concerns, including the risk of respiratory depression, as endorsed by the FDA guidelines and expert panel opinion 1. When considering pain management options for children, it is essential to prioritize their safety and well-being. The use of tramadol in pediatric patients has been associated with serious adverse effects, including reduced or slow breathing, which can be life-threatening 1. Key safety considerations for tramadol use in pediatric patients include:

  • Risk of respiratory depression, especially in children with obesity, sleep apnea, or respiratory conditions
  • Potential for dependence and withdrawal symptoms
  • Increased risk of serotonin syndrome when combined with other serotonergic medications Given the potential risks and limited benefits, tramadol should only be considered when other pain management options are inadequate, and under close medical supervision. For children 12-17 years old, if tramadol is deemed necessary, a starting dose of 50 mg every 4-6 hours as needed for pain, with a maximum daily dose of 200 mg/day, and short-term use only, typically 3-5 days, may be considered, while closely monitoring for adverse reactions 1. It is crucial to educate parents on proper administration and potential warning signs of adverse reactions, ensuring the safe use of tramadol in pediatric patients, if it is deemed necessary by a healthcare professional.

From the FDA Drug Label

The safety and efficacy of tramadol hydrochloride in patients under 16 years of age have not been established. The use of tramadol hydrochloride in the pediatric population is not recommended 2

  • The safety of tramadol in pediatric patients is not established.
  • The use of tramadol in patients under 16 years of age is not recommended.

From the Research

Safety of Tramadol in Pediatric Patients

The safety of tramadol in pediatric patients is a concern due to the potential for serious adverse events, such as respiratory depression. Several studies have investigated the safety and efficacy of tramadol in children, including:

  • A 2018 study published in Frontiers in Pharmacology, which highlighted the importance of personalized dosing of tramadol in children based on CYP2D6 activity to minimize the risk of adverse events 3.
  • A 2005 study published in Prescrire International, which raised concerns about the safety of tramadol in children due to the risk of accidental overdose and respiratory depression 4.
  • A 2024 study published in Pharmaceuticals, which found that tramadol was associated with a high risk of respiratory depression, particularly in pediatric patients, and that concomitant use of CYP2D6 inhibitors, opioids, benzodiazepines, and antidepressants increased this risk 5.
  • A 2019 study published in The Clinical Journal of Pain, which discussed the use of tramadol in pediatric palliative care and highlighted the need for careful monitoring and dose adjustment to minimize the risk of adverse events 6.
  • A 2015 systematic review published in The Cochrane Database of Systematic Reviews, which found that the evidence for the safety and efficacy of tramadol in children was limited and of low quality, but suggested that tramadol may be effective for postoperative pain relief in children when used at appropriate doses and with careful monitoring 7.

Key Findings

Some key findings from these studies include:

  • Tramadol can be effective for pain relief in children, but the risk of adverse events, such as respiratory depression, must be carefully considered and monitored.
  • Personalized dosing of tramadol based on CYP2D6 activity may help minimize the risk of adverse events in children.
  • Concomitant use of certain medications, such as CYP2D6 inhibitors, opioids, benzodiazepines, and antidepressants, can increase the risk of adverse events associated with tramadol.
  • The evidence for the safety and efficacy of tramadol in children is limited and of low quality, highlighting the need for further research in this area.

Adverse Events

Adverse events associated with tramadol use in children include:

  • Respiratory depression
  • Accidental overdose
  • Postoperative nausea and vomiting (PONV)
  • Other opioid-related adverse events, such as sedation and constipation. These adverse events can be serious and potentially life-threatening, emphasizing the need for careful monitoring and dose adjustment when using tramadol in pediatric patients, as noted in studies 3, 4, 5, 6, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.